Evusheld US FDA EUA
9 December 2021 07:00 GMT Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Only antibody therapy authorised in US for pre-exposure prophylaxis Pivotal phase III data showed robust efficacy and long-term protection with one dose in high-risk population AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19,